NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

TLDR

The NCCN Soft Tissue Sarcoma Guidelines include a subsection on GIST treatment, and the standard of practice rapidly changed after the introduction of effective targeted therapies such as imatinib and sunitinib. The NCCN convened a multidisciplinary panel to expand existing guidelines for GIST and identify future research areas, meeting first in 2003 and again in 2006. The Task Force, made up of NCCN faculty and leading experts from the United States, Europe, and Australia, met in 2003 and 2006 to develop the updated guidelines. Reference: JNCCN 2007;5[Suppl 2]:S1–S29.

Abstract

The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST. ( JNCCN 2007;5[Suppl 2]:S1–S29)